Startups
FluoSphera has developed in vitro human biosystems that mimic essential features of human body organization.
FluoSphera's biosystems generate data that predict much better the effects of drugs on patients, thus reducing the costs of drug development failure up to several hundreds of million dollars per drug.
Using this technology, FluoSphera proposes R&D services to pharmaceutical companies willing to de-risk drug development projects.
Drug profiling with our biosystems allows the discovery of more efficient drugs for the patients, with less adverse side effects, and it contributes to reduce animal experimentation.
FluoSphera's biosystems generate data that predict much better the effects of drugs on patients, thus reducing the costs of drug development failure up to several hundreds of million dollars per drug.
Using this technology, FluoSphera proposes R&D services to pharmaceutical companies willing to de-risk drug development projects.
Drug profiling with our biosystems allows the discovery of more efficient drugs for the patients, with less adverse side effects, and it contributes to reduce animal experimentation.
Overview
Location
Switzerland
Total raised
$3.71M
Investors 3
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| EFI Lake Geneva Ventures | lakegenevaventures.com | |
| Jul 7, 2023 | Mountain Labs | mountainlabs.ch |
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jan 25, 2024 | Grant | $1.27M | |
| Mar 1, 2023 | Pre-seed round | $1M |
Mentions in press and media 26
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 16, 2026 | Ternary Therapeutics targets “undruggable” proteins with AI-designed molecular glues, raising €4.1 million | London-based BioTech startup Ternary Therapeutics has raised €4.1 million (£3.6 million) in Seed funding to scale an AI platform designed to create a new class of medicines known as molecular glues. The round was led by European venture fir... |
| Jan 20, 2026 | Soulmates Ventures Backs FluoSphera Rethinking Preclinical Drug Development | With Soulmates Ventures’ support, Fluosphera is building scalable, human-relevant preclinical models to reduce drug development failure Its multiplexed platform enables early, decision-grade insights across multiple interacting human tissue... |
| Jan 13, 2026 | Orca Bio Secures $250M for Cell Therapy Launch and Pipeline Expansion | Orca Bio, a leader in cell therapy, recently raised $250 million. This significant capital influx ensures commercial readiness for Orca-T, its lead allogeneic T-cell immunotherapy. An FDA Prescription Drug User Fee Act (PDUFA) target action... |
| Jan 13, 2026 | FluoSphera Secures €1.23M to Revolutionize Drug Discovery with Human-Relevant Platform | FluoSphera, a Swiss biotech firm, secured €1.23 million. This vital funding propels its advanced drug discovery platform. The patented multi-tissue system offers animal-free, human-relevant testing. It predicts drug effects with high accura... |
| Jan 13, 2026 | FluoSphera raises CHF 1.15M to scale human-based preclinical platform | Drug development remains costly and inefficient, with over 90% of candidates failing in clinical trials due largely to the limits of traditional preclinical models. Conventional cell cultures and animal testing often fail to predict how com... |
| Jan 12, 2026 | Orca Bio Raises $250M in Aggregate Funding | Orca Bio, a Menlo Park, CA-based late-stage biotechnology company developing cell therapies, raised $250M in aggregate funding. The amount consisted of $250M in new equity capital including a Series F led by Lightspeed Venture Partners from... |
| Jan 12, 2026 | FluoSphera secures €1.23M to expand human-based preclinical platform | FluoSphera, a Swiss biotech startup focused on drug safety and efficacy testing, has raised €1.23 million (CHF1.15 million) in funding. The round was led by Soulmates Ventures and a Swiss business angel, with participation from IndieBio New... |
| Jan 12, 2026 | Marvell to Acquire XConn Technologies | Marvell Technology, Inc. (NASDAQ: MRVL), a Santa Clara, CA-based company which specializes in data infrastructure semiconductor solutions, acquired XConn Technologies, a San Jose, CA-based hybrid switch company supporting both CXL and PCIe ... |
| Jan 12, 2026 | Female-led Swiss BioTech FluoSphera secures €1.23 million to advance animal-free, human-relevant drug discovery | Geneva-based BioTech startup FluoSphera today announced that it has raised €1.23 million (CHF 1.15 million) in funding to make drug discovery faster, safer, and more human-relevant with its patented multi-tissue platform. The round was led ... |
Show more
Reviews 0
FAQ about FluoSphera SA
How much funding has FluoSphera SA raised?
FluoSphera SA has raised $3.71M in total across 3 funding rounds.
What funding rounds has FluoSphera SA raised?
Parsers VC lists 3 funding rounds of FluoSphera SA, among them a grant of $1.27M on Jan 25, 2024 and a pre-seed round of $1M on Mar 1, 2023.
Who has invested in FluoSphera SA?
Parsers VC lists 3 investors of FluoSphera SA, among them Mountain Labs and EFI Lake Geneva Ventures.
What has the press written about FluoSphera SA?
Parsers VC has collected 26 articles mentioning FluoSphera SA, among them “Ternary Therapeutics targets “undruggable” proteins with AI-designed molecular glues, raising €4.1 million” (Mar 16, 2026) and “Soulmates Ventures Backs FluoSphera Rethinking Preclinical Drug Development” (Jan 20, 2026).
Is FluoSphera SA still active?
FluoSphera SA is probably closed: its latest activity on Parsers VC dates from Sep 2, 2026.